Read about the latest developments in the world of lung cancer. You'll find articles from the last 24 months.
Lung Cancer in the News
March 2021
March 8, 2021:
Mental health issues surrounding lung cancer could take a greater toll on patients than the disease itself, experts say
(The Cavalier Daily)
March 4, 2021:
FDA approves lorlatinib for metastatic ALK-positive NSCLC
(U.S. FDA)
February 2021
February 28, 2021:
The Emotional Side of Lung Cancer
(WebMD)
February 26, 2021:
The Right to Breathe
(Cancer Wellness)
February 22, 2021:
FDA Approves Cemiplimab in Frontline PD-L1-High Advanced NSCLC
(Targeted Oncology)
February 3, 2021:
FDA grants accelerated approval to tepotinib for metastatic non-small cell lung cancer
(US FDA)
January 2021
January 4, 2021:
FDA grants priority review to Lorbrena for lung cancer subset”
(Healio News)
December 2020
December 18, 2020:
FDA approves osimertinib as adjuvant therapy for non-small cell lung cancer wit EGFR mutations
(US FDA)
December 8, 2020:
FDA grants breakthrough therapy designation to sotorasib for NSCLC with KRAS G12C mutation
(Cancer Network)
October 2020
October 29, 2020:
Roche EGFR mutation test approved by FDA as companion diagnostic for NSCLC
(genomeweb)
October 29, 2020:
FDA grants priority review to frontline cemiplimab for PD-L1-High advanced or metastatic NSCLC
(Targeted Oncology)
October 23, 2020:
FDA approves companion diagnostic to identify NTRK fusions in solid tumors for Vitrakvi
(US FDA)
October 20, 2020:
FDA Grants Priority Review to Osimertinib for Early-Stage EGFR-Mutant NSCLC
(Targeted Oncology)
October 20, 2020:
FDA grants priority review to Tagrisso for lung cancer subset
(HemOnc Today)
September 2020
September 4, 2020:
Charles Rudin, MD, PhD, on the KEYNOTE-603 lung cancer findings
(MedPage Today)
September 4, 2020:
FDA approves pralsetinib in RET fusion-positive NSCLC
(Targeted Oncology)
August 2020
August 27, 2020:
Second liquid biopsy OK’d for tumor profiling in all solid cancers
(MedPage Today)
August 20, 2020:
FDA grants priority review to fixed-dose Imfinzi for lung, bladder cancer
(HemOnc Today)
August 17, 2020:
FDA grants priority review to trilaciclib in chemotherapy-treated small cell lung cancer
(Targeted Oncology)
August 14, 2020:
Non-small cell lung cancer mortality rates decline sharply amid advances in treatment
(Healio News)
August 12, 2020:
Non-small cell lung cancer mortality rates decline sharply amid advances in treatment
(Healio)
August 11, 2020:
Ensartinib prolongs PFS vs. crizotinib in ALK-positive non-small cell lung cancer
(Healio)
August 8, 2020:
Another ALK Drug Tops Critzotinib in First-Line NSCLC
(MedPage)
August 7, 2020:
FDA approves first liquid biopsy next-generation sequencing companion diagnostic test
(US FDA)
August 5, 2020:
Lorlatinib prolongs PFS over crizotinib in ALK+ NSCLC, adds to existing data for FDA submission
(Targeted Oncology)
July 2020
July 31, 2020:
FDA grants breakthrough therapy designation to Tagrisso for lung cancer subset
(Healio)
June 2020
June 24, 2020:
FDA Initiates Pilot Program to Share Patient-Reported Outcomes from Cancer Clinical Trials
(Targeted Oncology)
June 16, 2020:
FDA approves pembrolizumab for adults and children with TMB-H solid tumors
(US FDA)
May 2020
May 29, 2020:
Pembrolizumab Added to Etoposide Plus Platinum Chemotherapy Provides Modest Survival Benefit in ES-SCLC
(Targeted Oncology)
May 29, 2020:
FDA approves ramucirumab plus erlotinib for first-line metastatic NSCLC
(U.S. FDA)
May 26, 2020:
FDA approves nivolumab plus ipilimumab and chemotherapy for first-line treatment of metastatic NSCLC
(US FDA)
May 25, 2020:
FDA grants breakthrough therapy status to two cancer therapies
(Healio)
May 22, 2020:
FDA approves brigatinib for frontline treatment of ALK-positive metastatic NSCLC
(Targeted Oncology)
May 18, 2020:
FDA approves atezolizumab for first-line treatment of metastatic NSCLC with high PD-L1 expression
(US FDA)
May 18, 2020:
FDA grants breakthrough designation to trastuzumab deruxtecan for HER+ mNSCLC
(Targeted Oncology)
May 15, 2020:
FDA approves nivolumab plus ipilimumab for first-line mNSCLC (PD-L1 tumor expression ≥1%)
(U.S. FDA)
May 10, 2020:
FDA grants priority review to cancer therapies
(Healio)
May 8, 2020:
FDA approves selpercatinib for 3 RET-positive cancer types
(cancernetwork)
May 6, 2020:
FDA approves first targeted therapy to treat aggressive form of lung cancer
(U.S. FDA)
April 2020
April 28, 2020:
FDA approves new dosing regime for pembrolizumab
(U.S. FDA)
April 27, 2020:
FDA grants breakthrough designation to mobocertinib for EGFR Exon 20+ NSCLC
(Targeted Oncology)
April 14, 2020:
Frontline tisleizumab combination significantly improves PFS in nonsquamous NSCLC
(Targeted Oncology)
April 14, 2020:
FDA grants priority review to first-line lung cancer regimen
(Healio)
April 13, 2020:
Adjuvant osimertinib shows ‘overwhelming efficacy’ for EGFR-mutated lung cancer
(Healio)
April 2, 2020:
Tedopi vaccine shows positive survival in HLA-A2-positive advanced NSCLC
(Targeted Oncology)
March 2020
March 30, 2020:
FDA approved durvalumab for extensive-stage small cell lung cancer
(Targeted Oncology)
March 25, 2020:
Japanese regulators approve Merck KGaA Met Inhibitor with ArcherDX CDX
(Precision Oncology News)
March 25, 2020:
Four regimens receive priority review for lung cancer indications
(HemOnc Today)
March 23, 2020:
Therapy for stage IV non-small cell lung cancer without driver alterations: ASCO and OH (CCO) Joint Guideline Update
(J Clin Oncol)
March 17, 2020:
Durvalumab plus chemotherapy, without tremelimuab, extends OS in small cell lung cancer
(HemOncol Today)
February 2020
February 20, 2020:
Global study shows long-term survival benefit for a subset of patients with advanced lung cancer
(News Medical Life Sciences)
February 19, 2020:
FDA grants priority review to Roche’s Tecentriq monotherapy as first-line treatment of certain people with advanced non-small cell lung cancer
(Healio)
February 17, 2020:
FDA grants priority review to lurbinectedin for relapsed small cell lung cancer
(Healio)
February 11, 2020:
FDA grants capmatinib priority review for non-small cell lung cancer subset
(Healio)
January 2020
January 22, 2020:
Tislelizumab extends PFS in squamous non-small cell lung cancer
(Healio HemOncToday)
January 17, 2020:
Dana-Farber Cancer Institute to Establish Chen-Huang Center for EGFR Mutant Lung Cancers
(Targeted Oncology)
January 15, 2020:
FDA grants priority review to Opdivo and Yervoy combination for first-line non-small cell cell lung cancer
(Healio)
January 14, 2020:
Addition of pembrolizaumab to chemotherapy fails to extend OS in small cell lung cancer
(Healio)
January 8, 2020:
Facts & Figures 2020 Reports Largest one-year Drop in Cancer Mortality
(American Cancer Society)
January 7, 2020:
Merck’s Keytruda shows mixed results in lung cancer study
(BioSpace)
December 2019
December 17, 2019:
Standard of care chemoradiation for stage III non-small cell lung cancer is superior to two tested alternatives
(Medical Xpress)
December 13, 2019:
Exploratory analysis shows significant OS results from Keytruda in KRAS mutations
(BioSpace)
December 5, 2019:
A diet high in fiber and yogurt is associated with a lowered risk for lung cancer, finds VUMC study
(Vanderbilt Hustler)
December 4, 2019:
FLAURA trial update: osimertinib outperforms other TKIs for OS in advanced NSCLC
(Targeted Oncology)
December 3, 2019:
FDA approves Genentech’s Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-small cell lung cancer
(Genentech)
December 3, 2019:
Revisiting chemo in EGFR-mutant NSCLC
(MedPage Today)
December 2, 2019:
FDA grants priority review to Imfinzi for lung cancer subset
(Healio)
November 2019
November 26, 2019:
Phase III ALTA-1L trial shows promise for non-small cell lung cancer
(cancernetwork)
November 24, 2019:
Brigatinib confers durable PFS benefit in ALK-positive NSCLC
(Healio)
November 12, 2019:
Osimertinib established as preferred EGFR TKI treatment in EGFR-mutated NSCLC
(Targeted Oncology)
November 6, 2019:
Year in Review: Lung Cancer—New regimens, strategies, but immunotherapy continues dominion
(MedPage Today)
October 2019
October 28, 2019:
AstraZeneca reports promising lung cancer results from Phase III immunotherapy drug trial
(MedCity News)
October 10, 2019:
Opdivo-Yervoy combo prolongs survival in patients wit advanced NSCLC, phase 3 study shows
(Immuno-Oncology News)
October 8, 2019:
Anti-PD-1 success in advanced NSCLC persists
(MedPage Today)
October 7, 2019:
Add-on Cyramza Boosts PFS in First-Line EGFR Lung Cancer
(MedPage Today)
October 2, 2019:
Tecentriq prolongs survival of patients with advanced lung cancer beyond chemo, phase 3 study shows
(Immuno-Oncology News)
October 1, 2019:
Opdivo boosts long-term survival of advanced lung cancer patients, phase 3 trials show
(Immuno-Oncology News)
September 2019
September 29, 2019:
Data support ‘Best Drug First’ in EGFR-mutant NSCLC
(MedPage Today)
September 29, 2019:
Bristol-Myers Squibb announces final results from CheckMate-227 Part 1 demonstrating superior overall survival for Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) vs. chemotherapy in advanced non-small cell lung cancer
(PipelineReview.com)
September 27, 2019:
Atezolizumab extends OS for PD-L1 selected patients with non-small cell lung cancer
(Healio)
September 25, 2019:
Palliative care linked to survival in lung cancer patients
(Hospice News)
September 18, 2019:
Breathalyzer sniffs out potential cancer immunotherapy responders
(Genetic Engineering & Biotechnology News)
September 16, 2019:
Liquid biopsy equivalent to tissue in guiding treatment of NSCLC
(Targeted Oncology)
September 12, 2019:
Roche’s Tecentriq as a first line monotherapy helpe certain people with advanced on-small cell lung cancer live longer compared with chemotherapy
(Global Newswire)
September 10, 2019:
Nivolumab confers fivefold OS improvement over chemotherapy in advanced NSCLC
(Healio)
September 10, 2019:
Breakthrough for VATS in early lung cancer?
(MedPage Today)
September 9, 2019:
IASLC World Conference on Lung Cancer—Summary of the Presidential Symposium Research
(Yahoo Finance)
September 8, 2019:
IASCLC World Conference on Lung Cancer—Press Briefing Summary from Sunday, September 8
(Cision)
August 2019
August 22, 2019:
Added local Tx extended survival in advanced NSCLC
(MedPage Today)
August 9, 2019:
Osimertinib benefit maintained in new OS findings from FLAURA trial in EGFR+ NSCLC
(Targeted Oncology)
July 2019
July 14, 2019:
Correlation between high-dose radiation and lung cancer survival rate
(Medical News Bulletin)
July 12, 2019:
FDA grants orphan drug designation to Imfinzi for small cell lung cancer
(Healio)
July 10, 2019:
Pembrolizumab lengthens overall survival in patients with advanced lung cancer
(MDLinx)
July 5, 2019:
Pemetrexed, bevacizumab maintenance therapy benefits certain NSCLC subsets
(HemOnc Today)
July 3, 2019:
Imfinzi combo therapy extends survival of advanced SCLC patients, phase 3 trial shows
(Immuno-Oncology News)
June 2019
June 28, 2019:
Pfizer receives U.S. FDA approval for its oncology biosimilar, Zirabev™
(BioSpace)
June 18, 2019:
FDA approves Keytruda for metastatic small cell lung cancer
(Healio)
June 14, 2019:
Tecentriq combo prolongs life of lung cancer patients with liver metastases
(Immuno-Oncology News)
June 7, 2019:
Imfinzi still improving survival rates in advanced NSCLC patients, PACIFIC update shows
(Immuno-Oncology News)
June 1, 2019:
Updated results from KEYNOTE-001 show favorable 5-year OS rate in advanced NSCLC
(Targeted Oncology)
May 2019
May 9, 2019:
Burden of Proof: TMB predics response to combo immunotherapy
(MedPage Today)
